Daptomycin API Market Size, Share, Growth, Trends, and Global Industry Analysis: By Source (Fermentation-Based, Semi-Synthetic), By Application (Pharmaceutical Manufacturing, Research & Development, Hospital Use), By End User (Generic Drug Manufacturers, Branded Pharmaceutical Companies, Contract Manufacturing Organizations, Others) and Region Forecast 2020-2031

Daptomycin API Market size was valued at US$ 1,350.1 million in 2024 and is projected to reach US$ 2,483.9 million by 2031 at a CAGR of 9.1% from 2025-2031. Moreover, the U.S. Daptomycin API Market is projected to grow at 8.6% of CAGR over the forecast period.

The market refers to the global landscape for the production, supply, and commercialization of daptomycin as an active pharmaceutical ingredient. Daptomycin is a cyclic lipopeptide antibiotic primarily used for treating complex Gram-positive bacterial infections, including MRSA (methicillin-resistant Staphylococcus aureus). As an API, it is a critical raw material used by pharmaceutical manufacturers to formulate injectable antibiotics for hospital and specialty care use. The market includes API manufacturers, contract development and manufacturing organizations (CDMOs), and supply chain stakeholders catering to generic and branded formulations.

The market is witnessing steady growth, fuelled by the rising incidence of multidrug-resistant infections and the increasing demand for advanced antibiotics in hospital settings. Growing awareness about antimicrobial resistance (AMR) and global health authorities' efforts to support effective antibiotic development have further strengthened the demand for daptomycin-based formulations. Moreover, patent expirations of branded products are encouraging generic production, expanding market opportunities for API suppliers. Asia-Pacific, particularly India and China, has emerged as a key manufacturing hub due to cost-efficient production capabilities and regulatory approvals.

Facts & Figures

• In fact, over daptomycin is effective at doses of 4–6 mg/kg/day, making it suitable for short-duration, high-potency intravenous treatments in hospital settings.
• Over 700,000 deaths annually are linked to antimicrobial resistance (AMR) globally, driving strong demand for last-line antibiotics like daptomycin.
• Generic versions of daptomycin are approved in more than 60 countries, significantly increasing global demand for high-quality APIs.
• More than 70% of global daptomycin API is currently produced in Asia, led by India and China due to cost-efficient fermentation capabilities.
• Hospital-acquired infections (HAIs) affect 7–10% of patients globally, many of which are caused by drug-resistant Gram-positive bacteria treatable by daptomycin.
• A single batch of daptomycin API production can take 10–14 days due to its complex fermentation and purification processes.

Key Developments

• In August 2024, Biocon Pharma Limited, a wholly owned subsidiary of Biocon, received USFDA approval for its ANDA for Daptomycin for injection (500mg vial). The product is indicated for treating complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis in adults.
• In March 2024, Olon celebrated the 10th anniversary of its Daptomycin production, marking a decade of supplying this breakthrough antibiotic for skin infections. To meet rising global demand, the company announced a doubling of its production capacity. Manufactured through advanced fermentation and purification in its integrated biotech centers, Olon continues to deliver competitive and sustainable API solutions worldwide.

Daptomycin API Market Segmentation

Based on the source

• Fermentation-Based
• Semi-Synthetic

Based on source, the fermentation-based segment is anticipated to lead the Daptomycin API market, driven by its proven efficiency in producing high-purity, bioactive compounds. Daptomycin, being a naturally occurring lipopeptide antibiotic, is optimally derived through fermentation using Streptomyces roseosporus strains. This method ensures consistent yield, structural integrity, and scalability key factors in pharmaceutical manufacturing. Fermentation also aligns well with regulatory standards for purity and safety, making it the preferred approach among leading API producers. As demand for effective antibiotics grows, especially in hospital settings, the reliability and cost-effectiveness of fermentation-based production continue to strengthen its dominance in the global market.

Based on the application

• Pharmaceutical Manufacturing
• Research & Development
• Hospital Use

Based on application, the pharmaceutical manufacturing segment is expected to lead the Daptomycin API market due to the growing demand for large-scale production of generic and branded injectable antibiotics. As daptomycin is a critical active ingredient in treating severe Gram-positive infections, pharmaceutical companies are scaling up its production to meet rising global needs. The segment benefits from patent expirations, which have opened the market for generics, and from increasing investments in antibiotic manufacturing in both developed and emerging regions. With the need for consistent API quality, regulatory compliance, and cost-efficient bulk production, pharmaceutical manufacturing remains the primary driver of market demand.

Based on the end user

• Generic Drug Manufacturers
• Branded Pharmaceutical Companies
• Contract Manufacturing Organizations
• Others

Based on end user, the generic drug manufacturers segment is anticipated to dominate the Daptomycin API market, driven by the expiration of originator patents and the global push for affordable antibiotics. With healthcare systems under cost pressures, there is growing demand for high-quality, lower-cost alternatives to branded daptomycin formulations. Generic manufacturers are rapidly expanding production to supply hospitals and public health programs, especially in emerging markets. These companies require consistent, compliant API sources for large-scale production, fuelling the demand for daptomycin APIs. Their focus on cost-efficiency, volume manufacturing, and wide geographic reach positions them as the leading consumer group in the market.